PFIZER INC.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
- First Posted Date
- 2008-11-14
- Last Posted Date
- 2012-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT00791492
- Locations
- π΅πΉ
Unidade Clinica de Paramiloidose-Hospital Santo Antonio, Porto, Portugal
π¦π·FLENI-Hepatology and Organ Transplant Dept., Ciudad de Buenos Aires, Argentina
πΈπͺUmea University Hospital, Umea, Sweden
A Phase 1 Study To Evaluate The Effect Of Dimebon On The Pharmacokinetics Of Dextromethorphan
Phase 1
Completed
- Conditions
- Huntington DiseaseAlzheimer Disease
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2009-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00788047
- Locations
- πΊπΈ
Pfizer Investigational Site, New Haven, Connecticut, United States
Measure Exposure Of Tanezumab In Healthy Volunteers When Administering The Drug Subcutaneously
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Biological: tanezumab
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2020-10-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 76
- Registration Number
- NCT00788294
- Locations
- πΊπΈ
Pfizer Investigational Site, Cypress, California, United States
A Phase 2 Study To Evaluate The Safety Of Apixaban In Atrial Fibrillation
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 222
- Registration Number
- NCT00787150
- Locations
- π―π΅
Pfizer Investigational Site, Kumamoto, Japan
A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
Phase 2
Completed
- Conditions
- Ulcerative Colitis
- Interventions
- Drug: CP- 690 550Other: placebo
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2013-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 195
- Registration Number
- NCT00787202
- Locations
- π¬π§
Pfizer Investigational Site, Manchester, United Kingdom
Long-Term Non-Interventional Study (NIS) To Investigate The Safety And Effectiveness Of MACUGEN In Patients With Neovascular Age-Related Macular Degeneration Under Conditions Of Routine Clinical Practice
Completed
- Conditions
- Age-related Macular Degeneration
- Interventions
- Other: no intervention
- First Posted Date
- 2008-11-07
- Last Posted Date
- 2018-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 108
- Registration Number
- NCT00787319
- Locations
- π¨πΏ
Pfizer Investigational Site, Usti nad Labem, Czechia
Phase1, Single Dose, Crossover Study to Determine Bioequivalence
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2010-09-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 37
- Registration Number
- NCT00786240
- Locations
- πΈπ¬
Pfizer Investigational Site, Singapore, Singapore
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.
Phase 1
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 327
- Registration Number
- NCT00784719
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
Research Of Quality Of Life And Safety Outcomes Of Postmenopausal Breast Cancer Patients Switching From Tamoxifen Therapy To Aromatase Inhibitor Therapy
Completed
- Conditions
- Breast Neoplasms
- Interventions
- Other: Aromatase inhibitors
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2012-03-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 344
- Registration Number
- NCT00784888
- Locations
- πΉπ·
Pfizer Investigational Site, Trabzon, Turkey
A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis
Phase 2
Terminated
- Conditions
- Endometriosis
- Interventions
- Biological: TanezumabDrug: Placebo
- First Posted Date
- 2008-11-04
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT00784693
- Locations
- πΊπΈ
Women's Healthcare Group, Overland Park, Kansas, United States
πΊπΈN.E.C.C.R, Fall River LLC, Fall River, Massachusetts, United States
πΊπΈMount Vernon Clinical Research, Atlanta, Georgia, United States
Β© Copyright 2025. All Rights Reserved by MedPath